Oncotelic Therapeutics OTLC
OTC OTLC
$0.02 +0.00 (+0.00%)
At close: Oct 15, 2026 · 4:00 PM EDT

Oncotelic Therapeutics (OTLC) EBIT Margin (2012 - 2026)

Updated

Oncotelic Therapeutics (OTLC) posted EBIT Margin of -337.43% for Q2 2026.

Analysis

Oncotelic Therapeutics (OTLC) EBIT Margin (2012 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, EBIT Margin at Oncotelic Therapeutics was -1227.83%; for FY2023, it came in at -9497.16%.

  • Annual EBIT Margin shows a three-year change of -9061.47 percentage points (FY2020 to FY2023).
  • In prior years, Oncotelic Therapeutics' EBIT Margin was -1825.18% in FY2021 (-1389.49 pp) and -435.69% in FY2020.
  • The Q2 2026 figure stands as the highest quarterly EBIT Margin since Q3 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Eli Lilly 1,109.83 Bn 1,078.42 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 610.61 Bn 529.14 Bn 17.26 Bn 28.21%
3 AbbVie 500.66 Bn 473.77 Bn 12.70 Bn 37.86%
4 Merck 354.64 Bn 309.02 Bn 12.21 Bn -3.52%
5 Novartis Ag 291.14 Bn 255.13 Bn 11.24 Bn 32.97%
6 Astrazeneca 254.18 Bn 227.87 Bn 12.86 Bn 20.57%
7 Amgen 229.46 Bn 184.86 Bn 7.24 Bn 34.95%
8 Gilead Sciences 190.33 Bn 164.53 Bn 6.22 Bn -133.21%
9 Pfizer 167.92 Bn 114.57 Bn 10.94 Bn 28.37%
10 Oncotelic Therapeutics 8.28 Mn 7.42 Mn - -337.43%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -337.43%
Sep 30, 2023 20.68%
Mar 31, 2021 -407.58%
Jun 30, 2020 0.99%
Mar 31, 2020 -777.06%
Sep 30, 2013 -2,786.32%
Dec 31, 2012 -3,978.57%
Mar 31, 2012 -1,653.51%
API Access

Oncotelic Therapeutics EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=OTLC&period=max&api_key=YOUR_API_KEY